Sector News

Valeant's debt-fueled castoffs continue with half-priced Obagi sale

July 17, 2017
Life sciences

It’s been more than a year since analysts first said Valeant could sell off its Obagi Medical Products business to raise cash, but the Canadian drugmaker has finally found a taker.

An investment fund has agreed to fork over $190 million for the dermatology business, which Valeant grabbed in 2013. The drugmaker will use that money to pay down the M&A-fueled debt mountain that’s been worrying investors and holding down shares.

“The sale of Obagi marks additional progress in our efforts to streamline our operations and reduce debt,” Valeant CEO Joseph Papa said in a statement announcing the sale to Haitong International Zhonghua Finance Acquisition Fund I.

Longtime Valeant critic David Maris, however, was quick to point out that Valeant is selling Obagi for half the sum it originally spent on the buy; the $190 million sale price falls 56.5% below the $437 million Valeant handed over to acquire it, he wrote in a Monday note to clients.

And while Valeant “continues to make progress toward its asset sales and total debt reduction targets,” the way Maris sees it, its efforts so far haven’t been enough.

For all of Papa’s talk of asset sales, Valeant has only pulled off a few. Late 2016 talks with Takeda over a potential $10 billion sale of its gastrointestinal unit Salix fell through, and a rumored divestment of eyecare giant Bausch & Lomb hasn’t yet materialized. Before the Obagi announcement, the company had managed just a $2.1 billion sale of cancer vaccine maker Dendreon and some skincare brands, along with a $930 million sale of iNova Pharmaceuticals.

“In our opinion, leverage remains high and we do not believe that recent deals … have had a significant deleveraging impact,” Maris wrote.

Valeant hasn’t been relying on castoffs to pay down its debt, though. Last week, it said it would redeem $500 million in senior notes, bringing its debt reduction tally to $4.8 billion since the end of 2016’s Q1.

Of course, debt is far from Valeant’s only problem. The company has suffered under struggling sales, a slew of investigations and price-hike pushback in addition to the debt-default worries.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.